Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab

IMPORTANCE: Consolidative durvalumab after definitive chemoradiation for unresectable locally advanced non–small cell lung cancer (NSCLC) can significantly improve progression-free survival (PFS) and overall survival (OS), as shown in the PACIFIC trial. However, whether patients with driver variatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yufei, Zhang, Zhe, Rinsurongkawong, Waree, Gay, Carl M., Le, Xiuning, Ning, Matthew S., Lewis, Jeff, Rinsurongkawong, Vadeerat, Lee, J. Jack, Roth, Jack, Swisher, Stephen, Gandhi, Saumil, Lee, Percy P., Gibbons, Don L., Vaporciyan, Ara A., Heymach, John V., Zhang, Jianjun, Lin, Steven H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171557/
https://www.ncbi.nlm.nih.gov/pubmed/35666500
http://dx.doi.org/10.1001/jamanetworkopen.2022.15589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171557/
https://www.ncbi.nlm.nih.gov/pubmed/35666500
http://dx.doi.org/10.1001/jamanetworkopen.2022.15589

Ejemplares similares